Postherpetic neuralgia MedDRA version: 8.1 Level: LLT Classification code 10029223
Conditions
Interventions
Product Name: [S,S]-Reboxetine Succinate
Product Code: PNU-165442G
Pharmaceutical Form: Tablet
INN or Proposed INN: (+)-[S,S]-Reboxetine Succinate
Current Sponsor code: PNU-165442G
Other descriptive n
Sponsors
Pfizer, S.A.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: · Male or female of any race at least 18 years of age. · Female patients must be postmenopausal, or surgically sterilized, or (if they are of childbearing potential) they must be nonpregnant and nonlactating and must be using appropriate methods of contraception (including barrier or hormonal method). Women of childbearing potential must have a confirmed negative urine pregnancy test at the screening visit (V1) and at the randomization visit (V2). · Patients must have pain present for more than 3 months after healing of the herpes zoster skin rash. There is no upper limit on the duration of PHN. · Patients at V1 must have a score =40 mm on the Pain Visual Analogue Scale (VAS). · Normal chest x-ray within 1 year prior to V1; or stable x-ray defined as no clinically significant change from previous exam (if none available, x-ray must be taken at V1). Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: · Malignancy within the past 2 years with the exception of basal cell carcinoma. · Patients with significant hepatic impairment (i.e. AST/ALT>2x ULN, Total bilirubin >2 x ULN) · Clinically significant abnormal 12-lead ECG (in the opinion of the investigator). · Neurological disorders unrelated to PHN that may confuse the assessment of neuropathic pain. · Any pain or other condition that may confound assessment or self-evaluation of the pain due to PHN. · History of chronic hepatitis B or C, acute hepatitis A, B or C within the past 3 months, or HIV infection. · Skin conditions in the area affected by the neuropathy that (in the opinion of the investigator) could alter sensation. · Patients who have undergone neurolytic or neurosurgical therapy including skin excisions for PHN. · Amputations other than toes. · Administration of any investigational drug and/or agent within 30 days prior to screening. · Use of prohibited medications, in the absence of appropriate washout phases. · Abuse of drugs or alcohol within the last 2 years. · Any serious or unstable medical conditions that, in the opinion of the investigator, would compromise participation in the trial. · Any history of, or current, significant psychiatric disorder e.g. any DSM-IV Axis I or II Disorder or patients judged clinically to be a serious suicidal risk. · History of recurrent syncope or hypotension (systolic 70%) has been excluded by appropriate investigation. · History of uncontrolled narrow angle glaucoma. · History of epilepsy or seizure disorder. · Previous exposure to reboxetine. · History of urinary retention or prostatic hypertrophy (unless surgically corrected e.g. by TURP). · History of heart failure (NYHA class =2), myocardial infarction or unstable angina.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: To assess the long-term safety and tolerability of [S,S]-RBX in patients with PHN.;Secondary Objective: To assess the effect of long-term treatment with [S,S]-RBX on neuropathic pain and health-related quality of life in patients with PHN. To assess the effect of long-term treatment with [S,S]-RBX on the use of pain-related medications for the management of PHN. ;Primary end point(s): · Vital signs · Physical examination · 12-lead ECG · Hematology/Biochemistry · Adverse events | — |
Countries
Lithuania, Spain, Sweden, United Kingdom
Outcome results
None listed